NO2872646T3 - - Google Patents
Info
- Publication number
- NO2872646T3 NO2872646T3 NO13735334A NO13735334A NO2872646T3 NO 2872646 T3 NO2872646 T3 NO 2872646T3 NO 13735334 A NO13735334 A NO 13735334A NO 13735334 A NO13735334 A NO 13735334A NO 2872646 T3 NO2872646 T3 NO 2872646T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305836 | 2012-07-12 | ||
| EP13735334.8A EP2872646B1 (en) | 2012-07-12 | 2013-07-12 | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| PCT/EP2013/064808 WO2014009535A2 (en) | 2012-07-12 | 2013-07-12 | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2872646T3 true NO2872646T3 (US20100136652A1-20100603-C00002.png) | 2018-01-27 |
Family
ID=48782367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO13735334A NO2872646T3 (US20100136652A1-20100603-C00002.png) | 2012-07-12 | 2013-07-12 |
Country Status (8)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2648176T3 (es) * | 2012-07-12 | 2017-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos de predicción del tiempo de supervivencia y de la respuesta al tratamiento de un paciente que padece un cáncer sólido con un distintivo de al menos 7 genes |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| WO2015094995A2 (en) * | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3084003A4 (en) * | 2013-12-17 | 2017-07-19 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
| CA2958573A1 (en) * | 2014-08-19 | 2016-02-25 | National University Corporation Okayama University | Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist |
| WO2016049276A1 (en) * | 2014-09-25 | 2016-03-31 | Moffitt Genetics Corporation | Prognostic tumor biomarkers |
| AU2015343339A1 (en) * | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
| CN106796235B (zh) | 2014-11-03 | 2021-01-29 | 豪夫迈·罗氏有限公司 | 用于检测t细胞免疫子集的测定法及其使用方法 |
| AU2015360736A1 (en) | 2014-12-09 | 2017-06-01 | Merck Sharp & Dohme Corp. | System and methods for deriving gene signature biomarkers of response to PD-1 antagonists |
| EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| CN114907481A (zh) | 2015-03-23 | 2022-08-16 | 震动疗法股份有限公司 | Icos的抗体 |
| EP3073268A1 (en) * | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
| ES2844799T3 (es) * | 2015-04-17 | 2021-07-22 | Merck Sharp & Dohme | Biomarcadores sanguíneos de sensibilidad tumoral a antagonistas de PD-1 |
| IL255769B2 (en) | 2015-05-20 | 2023-09-01 | Broad Inst Inc | shared neoantigens |
| JP6831112B2 (ja) * | 2015-10-15 | 2021-02-17 | 国立大学法人京都大学 | Ｐｄ−１経路阻害薬の著効例を予測するためのバイオマーカー |
| CN108350505A (zh) * | 2015-10-22 | 2018-07-31 | 震动疗法股份有限公司 | 用于测定icos表达的基因标志 |
| WO2017096458A1 (en) * | 2015-12-07 | 2017-06-15 | Ontario Institute For Cancer Research (Oicr) | Immune gene signature predictive of anthracycline benefit |
| EP3442593A4 (en) * | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
| WO2017194556A1 (en) * | 2016-05-09 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for classifying patients with a solid cancer |
| CN110087673A (zh) * | 2016-07-19 | 2019-08-02 | 梯瓦制药澳大利亚股份有限公司 | 抗cd47联合治疗 |
| WO2018045346A1 (en) * | 2016-09-01 | 2018-03-08 | Autotelic Llc | Methods for treating cancer and determining efficacy of treatment |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP2020523022A (ja) * | 2017-06-14 | 2020-08-06 | アイカーン スクール オブ メディシン アット マウント サイナイ | 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 |
| EP3639277A2 (en) * | 2017-06-16 | 2020-04-22 | Nantomics, LLC | Prognostic indicators of poor outcomes in praegnant metastatic breast cancer cohort |
| BR112021024374A8 (pt) | 2019-06-03 | 2022-12-06 | Inst Nat Sante Rech Med | Método para modular um regime de tratamento |
| KR20220094193A (ko) | 2019-11-07 | 2022-07-05 | 온세르나 테라퓨틱스, 인크. | 종양 미세환경의 분류 |
| AU2021248833A1 (en) | 2020-04-01 | 2022-09-22 | Avalo Therapeutics, Inc. | Methods and treatment involving excess free LIGHT |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CA3187765A1 (en) * | 2020-06-18 | 2022-12-23 | Macrogenics, Inc. | Use of bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies |
| CN115843335A (zh) | 2020-06-30 | 2023-03-24 | 国家医疗保健研究所 | 用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法 |
| EP4172621A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| WO2023175366A1 (en) | 2022-03-17 | 2023-09-21 | Veracyte | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| US5132432A (en) | 1989-09-22 | 1992-07-21 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5338854A (en) | 1991-02-13 | 1994-08-16 | Molecular Probes, Inc. | Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5262357A (en) | 1991-11-22 | 1993-11-16 | The Regents Of The University Of California | Low temperature thin films formed from nanocrystal precursors |
| US5505928A (en) | 1991-11-22 | 1996-04-09 | The Regents Of University Of California | Preparation of III-V semiconductor nanocrystals |
| US6048616A (en) | 1993-04-21 | 2000-04-11 | Philips Electronics N.A. Corp. | Encapsulated quantum sized doped semiconductor particles and method of manufacturing same |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5571018A (en) | 1994-11-23 | 1996-11-05 | Motorola, Inc. | Arrangement for simulating indirect fire in combat training |
| US5690807A (en) | 1995-08-03 | 1997-11-25 | Massachusetts Institute Of Technology | Method for producing semiconductor particles |
| US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
| US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
| US5696157A (en) | 1996-11-15 | 1997-12-09 | Molecular Probes, Inc. | Sulfonated derivatives of 7-aminocoumarin |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6617583B1 (en) | 1998-09-18 | 2003-09-09 | Massachusetts Institute Of Technology | Inventory control |
| US6114038A (en) | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
| US6855202B2 (en) | 2001-11-30 | 2005-02-15 | The Regents Of The University Of California | Shaped nanocrystal particles and methods for making the same |
| WO2000068692A1 (en) | 1999-05-07 | 2000-11-16 | Quantum Dot Corporation | A method of detecting an analyte using semiconductor nanocrystals |
| US6306736B1 (en) | 2000-02-04 | 2001-10-23 | The Regents Of The University Of California | Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process |
| US6225198B1 (en) | 2000-02-04 | 2001-05-01 | The Regents Of The University Of California | Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process |
| US6500622B2 (en) | 2000-03-22 | 2002-12-31 | Quantum Dot Corporation | Methods of using semiconductor nanocrystals in bead-based nucleic acid assays |
| AU2001275078A1 (en) | 2000-06-01 | 2001-12-11 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
| ATE415399T1 (de) | 2000-08-04 | 2008-12-15 | Molecular Probes Inc | Kondensierte ringe enthaltende 1,2-dihydro-7- hydroxychinolinderivate |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
| US6709929B2 (en) | 2001-06-25 | 2004-03-23 | North Carolina State University | Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates |
| EP2218762A3 (en) | 2001-07-20 | 2010-09-29 | Life Technologies Corporation | Luminescent nanoparticles and methods for their preparation |
| AU2003284880A1 (en) * | 2002-10-24 | 2004-05-13 | Duke University | Evaluation of breast cancer states and outcomes using gene expression profiles |
| US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| ES2330441T3 (es) | 2003-06-24 | 2009-12-10 | Ventana Medical Systems, Inc. | Deposito de metal catalizado por una enzima para la deteccion in situ mejorada de epitopos inmunohistoquimicos y secuencias de acido nucleico. |
| US7642064B2 (en) | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
| US20060246523A1 (en) | 2005-04-28 | 2006-11-02 | Christopher Bieniarz | Antibody conjugates |
| CA2606018A1 (en) | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Nanoparticle conjugates |
| AU2006244885B2 (en) * | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| ES2804129T3 (es) | 2005-11-23 | 2021-02-03 | Ventana Med Syst Inc | Conjugado anticuerpo-enzima |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US20100021424A1 (en) * | 2006-06-02 | 2010-01-28 | Vincent Brichard | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy |
| CN101970664B (zh) * | 2008-01-16 | 2013-08-21 | 林希龙 | 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞 |
| WO2010144192A1 (en) | 2009-05-05 | 2010-12-16 | Children's Medical Center Corporation | Prognosis indicators for solid human tumors |
| SG177699A1 (en) * | 2009-07-20 | 2012-02-28 | Genentech Inc | Gene expression markers for crohn's disease |
| EP2507397A4 (en) * | 2009-12-01 | 2013-05-01 | Compendia Bioscience Inc | CLASSIFICATION OF CANCERS |
| WO2011094483A2 (en) * | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| ES2648176T3 (es) * | 2012-07-12 | 2017-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos de predicción del tiempo de supervivencia y de la respuesta al tratamiento de un paciente que padece un cáncer sólido con un distintivo de al menos 7 genes |
-
2013
- 2013-07-12 ES ES13735334.8T patent/ES2648176T3/es active Active
- 2013-07-12 PL PL13735334T patent/PL2872646T3/pl unknown
- 2013-07-12 EP EP13735334.8A patent/EP2872646B1/en active Active
- 2013-07-12 US US14/413,856 patent/US11242564B2/en active Active
- 2013-07-12 NO NO13735334A patent/NO2872646T3/no unknown
- 2013-07-12 WO PCT/EP2013/064808 patent/WO2014009535A2/en active Application Filing
- 2013-07-12 DK DK13735334.8T patent/DK2872646T3/en active
- 2013-07-12 JP JP2015521016A patent/JP6923291B2/ja active Active
-
2019
- 2019-05-28 JP JP2019099354A patent/JP6936277B2/ja active Active
-
2021
- 2021-07-07 JP JP2021112781A patent/JP7378443B2/ja active Active
- 2021-12-27 US US17/562,111 patent/US20220259665A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150203919A1 (en) | 2015-07-23 |
| JP2015528698A (ja) | 2015-10-01 |
| EP2872646A2 (en) | 2015-05-20 |
| US11242564B2 (en) | 2022-02-08 |
| PL2872646T3 (pl) | 2018-03-30 |
| JP7378443B2 (ja) | 2023-11-13 |
| DK2872646T3 (en) | 2017-12-04 |
| EP2872646B1 (en) | 2017-08-30 |
| JP6936277B2 (ja) | 2021-09-15 |
| WO2014009535A2 (en) | 2014-01-16 |
| JP6923291B2 (ja) | 2021-08-18 |
| US20220259665A1 (en) | 2022-08-18 |
| JP2021166539A (ja) | 2021-10-21 |
| WO2014009535A3 (en) | 2014-04-17 |
| JP2019162138A (ja) | 2019-09-26 |
| ES2648176T3 (es) | 2017-12-28 |
